XML 251 R168.htm IDEA: XBRL DOCUMENT v3.20.4
Transaction with related parties (Details 1)
$ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Disclosure of transactions between related parties [line items]      
Net sales to third parties from continuing operations $ 48,659 $ 47,445 $ 44,751
Executive Commitee members 13 15 17
Non-executive directors 14 13 13
Roche Holding AG [member]      
Disclosure of transactions between related parties [line items]      
Proportion of voting rights held in associate 33.30% 33.30% 33.30%
Genentech / Roche [member]      
Disclosure of transactions between related parties [line items]      
Net expense, royalties cost sharing and profit sharing $ (217) $ (101) $ (34)
Number of contracts with related parties 2    
Genentech / Roche [member] | Lucentis [member]      
Disclosure of transactions between related parties [line items]      
Net sales to third parties from continuing operations $ 1,900 2,100 2,000
Genentech / Roche [member] | Xolair [member]      
Disclosure of transactions between related parties [line items]      
Net sales to third parties from continuing operations $ 1,300 $ 1,200 $ 1,000
Spark Therapeutics, Inc. [member]      
Disclosure of transactions between related parties [line items]      
Number of contracts with related parties 1